Spero Therapeutics to Join H.C. Wainwright BioConnect Conference

May 16, 2024 -- Spero Therapeutics Inc. (Nasdaq: SPRO), an innovative biopharmaceutical company in the clinical-stage with multiple assets, has announced that its President and CEO, Sath Shukla, will take part in a fireside chat and be available for personal meetings during the H.C. Wainwright 2nd Annual BioConnect Investor Conference. This event is scheduled to take place at the NASDAQ World Headquarters in New York, NY on Monday, May 20, 2024. 

Spero Therapeutics, based in Cambridge, Massachusetts, is dedicated to discovering and developing new treatments for rare diseases and bacterial infections that are resistant to multiple drugs. One of their primary focuses is on their lead product candidate, SPR720. This drug is being developed as a novel oral treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD), a rare lung disease caused by non-tuberculous mycobacterial infections. SPR720 is currently in a Phase 2A proof of concept study.

In addition to SPR720, Spero Therapeutics is also advancing Tebipenem HBr, an investigational oral drug, which is in a Phase 3 registrational trial. This drug is intended to treat complicated urinary tract infections (cUTI), including pyelonephritis. For the commercialization of Tebipenem HBr, Spero has granted an exclusive license to GSK, except for certain Asian territories.

Another notable development in Spero’s pipeline is SPR206, an investigational intravenous drug designed as a next-generation polymyxin. This drug has demonstrated antibiotic activity against multi-drug resistant Gram-negative pathogens in preclinical studies. These pathogens include carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. The FDA has cleared an Investigational New Drug (IND) application, allowing SPR206 to proceed into a Phase 2 clinical trial. This trial will involve participants suffering from hospital-acquired or ventilator-associated bacterial pneumonia.

Spero Therapeutics, through its innovative approaches and pipeline, aims to address significant unmet medical needs in the treatment of rare diseases and multi-drug resistant bacterial infections. The company's participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ is an opportunity to engage with potential investors and stakeholders, sharing progress and future directions.

The conference, set for May 20, 2024, will feature a session where the company's strategies and developments will be discussed in detail. Attendees will be able to access the webcast through Spero Therapeutics’ website, with a replay available after the event concludes.

This event represents a significant platform for Spero Therapeutics to highlight its advancements and to potentially attract further investment to support its mission of developing life-saving treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!